๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuzhou
Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca62 First Affiliated Hospital of Fujian Medical University45 Merck Sharp & Dohme LLC39 Fujian Medical University Union Hospital39 Fujian Cancer Hospital35
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Fuzhou

1018 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116Advanced Solid Tumors
DrugsBNT324·Abiraterone·Itraconazole·Enzalutamide
DualityBio Inc.
Phase 1/2
862
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin
2023-08-17
Recruiting
Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
NCT06035679Breast Cancer Female
Youzhi Zhu
Not applicable
30
Fuzhou
2023-08-17
Active, closed
Study of XGEVAยฎ (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
NCT04586660Giant Cell Tumor of Bone
Amgen
Phase 4
36
Beijing, Fuzhou, Guangzhou, Harbin, Xi'an, Hangzhou
2023-08-17
Active, closed
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
NCT06577792Non Small Cell Lung Cancer
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Not yet open
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
NCT05969847Rectal Cancer
DrugsCapecitabine, Oxaliplatin·Envafolimab·Capox
ๆฑ ็•”
Phase 2
72
Fuzhou
2023-08-15
Recruiting
Selinexor in Combination With MTX+Ritu to Treat R/R CNSL
NCT05698147Central Nervous System Lymphoma
DrugsMethotrexate·Selinexor·Rituximab
Tong Chen, MD
Phase 1/2
30
Hefei, Beijing, Fuzhou, Zhengzhou, Shanghai
2023-08-03
Recruiting
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
NCT06038396Advanced Solid Tumor
DrugsRC118·RC148·Toripalimab
RemeGen Co., Ltd.
Phase 1/2
48
Fuzhou, Xiamen, Wuwei, Meizhou, Harbin, Nanyang, Xinyang, Zhengzhou
2023-08-03
Active, closed
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
NCT05587374Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
DrugsCadonilimab·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Active, closed
A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
NCT06044350Optic Neuromyelitis Spectrum Disease
Bio-Thera Solutions
Phase 2
162
Baotou, Beijing, Changsha, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou
2023-08-01
Recruiting
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
NCT05624099Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms
DrugCamrelizumab
Fujian Cancer Hospital
Phase 2
75
Fuzhou
2023-08-01
Recruiting
Safety and Effectiveness of TaurusTrioโ„ข Heart Valve System in Patients With Severe Aortic Regurgitation (AR)
NCT06101888Aortic Regurgitation
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
116
Beijing, Fuzhou, Xiamen, Guangzhou, Guangdong, Haerbin, Wuhan, Changsha
2023-08-01
Active, closed
Effects of Shanyu Pill in Older Adults With Sarcopenia
NCT05919368Sarcopenia
Fujian University of Traditional Chinese Medicine
Not applicable
192
Fuzhou, Guangzhou
2023-07-17
Recruiting
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
NCT06119490Toxic Epidermal Necrolysis
DrugsAbrocitinib·Tofacitinib
Peng Zhang
Phase EARLY_PHASE1
30
Fuzhou
2023-07-05
Not yet open
Association of Osmotic Drugs With Clinical Outcomes in Acute Large Hemispheric Infarction
NCT05914272Stroke
Nanfang Hospital, Southern Medical University
Observational
2,592
Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang
2023-07-01
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
DrugsGotistobart·Docetaxel
OncoC4, Inc.
Phase 3
630
Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou
2023-06-28
Recruiting
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332Breast Cancer, Triple Negative Breast Cancer
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Recruiting
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
NCT05837897Crohn's Disease
DrugVedolizumab
Takeda
Phase 3
408
Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou
2023-06-16
Recruiting
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
NCT05913089Non Small Cell Lung Cancer
DrugsAnlotinib hydrochloride·Benmelstobart
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
NCT05892354Locally Advanced Nasopharyngeal Carcinoma
First Affiliated Hospital of Guangxi Medical University
Not applicable
190
Fuzhou, Guangzhou, Huizhou, Guilin, Liuzhou, Nanning, Wuzhou, Yulin
2023-06-12
Recruiting
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3
DrugSafusidenib
Nuvation Bio Inc.
Phase 3
365
Beijing, Fuzhou, Guangzhou, Changsha, Shanghai, Chengdu
2023-06-05
Recruiting
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
NCT05891093Breast Cancer
DrugsTamoxifen·Fluzoparib·Anastrozole·Exemestane
Fudan University
Phase 3
766
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-01
Recruiting
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
NCT06441110Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active, Multicenter Study
DrugsBacillus Calmette-Guerin·Tislelizumab
Fujian Medical University Union Hospital
Phase 3
76
Fuzhou
2023-06-01
Active, closed
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566Small Cell Lung Cancer (SCLC)
DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan
Amgen
Phase 3
509
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Shijiazhuang, Harbin
2023-05-31
By invitation
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
NCT06186804cGvHD
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 2
64
Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou
2023-05-30
Active, closed
A Study of PM8002 in Combination With Chemotherapy in Patients With NEN
NCT05879055Neuroendocrine Neoplasm
DrugsFolfiri·Pumitamig
Biotheus Inc.
Phase 2
31
Chongqing, Fuzhou, Harbin, Zhengzhou, Jingzhou, Wuhan, Changsha, Yongzhou
2023-05-17
Recruiting
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
NCT05923255Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
Zhejiang University
Not applicable
568
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-05-14
Recruiting
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IVใ€Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
NCT05699655Immunotherapy Gastrict Cancer
DrugsTegafur Gimeracil Oteracil·Apatinib·Tislelizumab·Oxaliplatin
Fujian Cancer Hospital
Phase 2/3
130
Fuzhou
2023-05-10
Recruiting
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
NCT05862337Hepatocellular Carcinoma
DrugAnlotinib hydrochloride,Penpulimab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
DrugsSacituzumab Govitecan·Nab-paclitaxel·Capecitabine·Paclitaxel
Gilead Sciences
Phase 3
654
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou
2023-05-08
Recruiting
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
NCT05773820Advanced Solid Tumors
DrugWJB001
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
210
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang
2023-05-05
Not yet open
Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy
NCT05845372Acute Ischemic Stroke
Nanfang Hospital, Southern Medical University
Observational
2,592
Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang
2023-05-01
Recruiting
A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
NCT05938309Gastrointestinal Stromal Tumors
Fujian Medical University
Observational
194
Fuzhou
2023-05-01
Not yet open
YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT05767892Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsIvonescimab·Pemetrexed
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase 3
350
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2023-05-01
Recruiting
Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
NCT03734952Radiation Oncology
Fujian Medical University Union Hospital
Not applicable
537
Fuzhou
2023-05-01
Active, closed
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
DrugPimicotinib
Abbisko Therapeutics Co, Ltd
Phase 3
94
Bengbu, Beijing, Fuzhou, Guangzhou, Guiyang, Zhengzhou, Enshi, Wuhan
2023-04-27
Recruiting
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
NCT05744687Locally Advanced or Metastatic Breast Cancer
DrugSPH4336
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
374
Fuzhou, Guangzhou, Guiyang, Anyang, Luoyang, Pingxiang, Changchun, Yinchuan
2023-04-24
Active, closed
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer
DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Active, closed
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
NCT05816252Non-small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Osimertinib·Carboplatin·Pembrolizumab
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Active, closed
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
NCT05707377Primary Membranous Nephropathy
DrugsTacrolimus·Zanubrutinib
BeOne Medicines
Phase 2/3
178
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-04-17
Active, closed
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
NCT05126719Recurrent or Metastatic Nasopharyngeal Carcinoma
Lepu Biopharma Co., Ltd.
Phase 2
238
Beijing, Chongqing, Fuzhou, Guangzhou, Maoming, Shantou, Shaoguan, Zhongshan
2023-04-06
Active, closed
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2
999
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou
2023-04-03
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Bortezomib·Pomalidomide
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Recruiting
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
NCT06050980NSCLC
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
NCT05718895Advanced/Metastatic Solid Tumors
DrugATG-022
Antengene Biologics Limited
Phase 1
156
Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai
2023-03-27
Recruiting
PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients
NCT05704166Acute Lung Injury, Prevention
Fujian Medical University Union Hospital
Phase 2
214
Fuzhou
2023-03-16
Recruiting
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
NCT06010342Solid Tumor
Teligene US
Phase 2
60
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2023-03-16
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Active, closed
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
NCT05744427Advanced Solid Tumor
DrugJSKN003
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Haโ€™erbin, Hefei, Jinan
2023-03-15
Active, closed
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
NCT05735496Advanced Cancer
DrugTQB2102
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
219
Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an
2023-03-09
Recruiting
The Study of ICP-248 in Patients With Mature B-cell Malignancies
NCT05728658Hematological Malignancies
DrugsICP-248·Orelabrutinib·Rituximab
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Recruiting
OH2 Injection in Melanoma
NCT05868707Melanoma
DrugOH2
Binhui Biopharmaceutical Co., Ltd.
Phase 3
340
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin
2023-03-08
Active, closed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
NCT05635708Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
DrugsBGB-A445·LBL-007·Nab-paclitaxel·Pemetrexed
BeiGene
Phase 2
400
Hefei, Beijing, Fuzhou, Baoding, Harbin, Zhengzhou, Wuhan, Nantong
2023-03-07
Active, closed
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
NCT05652894Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3
190
Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou
2023-02-28
Active, closed
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
NCT05716087Mantle Cell Lymphoma (MCL)
DrugRocbrutinib
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
62
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2023-02-21
Recruiting
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
NCT05319639Gastric Cancer Stage IV
DrugsLevo-Leucovorin·Irinotecan·Ivonescimab·Tislelizumab
Fujian Cancer Hospital
Phase 1/2
51
Fuzhou
2023-02-16
Active, closed
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
NCT05557838Hepatocellular Carcinoma
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Active, closed
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015Metastatic Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
377
Hefei, Beijing, Wanzhou, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Wuhan
2023-02-14
Active, closed
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
NCT05673785Lymphoma
DrugsBrentuximab Vedotin·Doxorubicin·Prednisone·Cyclophosphamide
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Active, closed
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
NCT05546866Non-small Cell Lung Cancer
DrugOsimertinib
AstraZeneca
Phase 2
51
Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou
2023-02-09
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 3
900
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-02-08
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
DrugsSacituzumab Govitecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-02-06
Recruiting
Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.
NCT07086391Carbapenem-Resistant Enterobacteriaceae Infection, Pneumonia - Bacterial
Fujian Medical University Union Hospital
Observational
144
Fuzhou
2023-02-01
Recruiting
Real-world Study Optimizing Nucleotide-analogues
NCT05937178Hepatitis B, Chronic
Huashan Hospital
Observational
20,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Nanning, Guiyang
2023-01-31
Active, closed
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
DrugsFluoropyrimidine·Bevacizumab biosimilar·Tislelizumab·Bevacizumab
BeiGene
Phase 1/2
113
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Shantou, Zhengzhou
2023-01-29
Active, closed
The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection๏ผˆBROAD๏ผ‰
NCT05659641Aortic Dissection, Aneurysm, Dissecting, Aneurysm, Vascular Diseases
Permed Biomedical Engineering Co., Ltd
Not applicable
259
Hefei, Chongqing, Fuzhou, Shijiazhuang, Harbin, Wuhan, Nanjing, Nanchang
2023-01-18
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
Abivax S.A.
Phase 3
1,116
Wuhu, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Shenyang
2023-01-16
Active, closed
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732Metastatic Non Small Cell Lung Cancer
DrugsDato-DXd·Pemetrexed·Cisplatin·Carboplatin
Daiichi Sankyo
Phase 3
1,170
Beijing, Beijing Sheng, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-01-11
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Carfilzomib·Dexamethasone
Bristol-Myers Squibb
Phase 3
606
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2023-01-10
Active, closed
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
NCT05661955Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma
DrugsBGB-A445·Tislelizumab
BeiGene
Phase 1/2
113
Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2023-01-09
Active, closed
Adult Spinal Muscular Atrophy (SMA) China Registry
NCT05618379Muscular Atrophy, Spinal
Biogen
Observational
200
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Nanchang
2023-01-06
Recruiting
3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
NCT06161207Gastric Cancer, Surgery
Fujian Medical University
Phase 3
702
Fuzhou
2023-01-03
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275Gastric Cancer, Peritoneal Metastases
Chinese Academy of Sciences
Observational
400
Beijing, Fuzhou, Guangzhou, Guiyang, Kunming, Taiyuan, Zhengzhou, Zhenjiang
2023-01-01
Recruiting
A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
NCT06277024Overall Response Rate
Fujian Medical University
Not applicable
50
Fuzhou
2023-01-01
Active, closed
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752Non Small Cell Lung Cancer, Breast Cancer
DrugYL202
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
80
Fuzhou, Changsha, Changchun, Hangzhou, Taizhou
2022-12-20
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
213
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Active, closed
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988Non-small Cell Lung Cancer
DrugsSunvozertinib·Pemetrexed·Carboplatin
Dizal Pharmaceuticals
Phase 3
324
รœrรผmqi, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-12-13
Active, closed
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT05629585Breast Cancer
DrugsDato-DXd·Durvalumab·Capecitabine·Pembrolizumab
AstraZeneca
Phase 3
1,174
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2022-11-28
Active, closed
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3
260
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Jinan, Qingdao
2022-11-21
Recruiting
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05678270Intrahepatic Cholangiocarcinoma (ICC)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
70
Hefei, Beijing, Fujian, Fuzhou, Foshan, Guangzhou, Shijiazhuang, Harbin
2022-11-15
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide
Pfizer
Phase 3
1,116
Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai
2022-11-10
Active, closed
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
NCT05486104Moderate to Severe Ulcerative Colitis
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 2
92
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2022-11-08
Not yet open
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
NCT05610332Locally Advanced Gastric Cancer
DrugCamrelizumab
Fujian Medical University
Phase 3
216
Fuzhou
2022-11-01
Active, closed
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
NCT05522231Advanced Renal Cell Carcinoma
DrugsFruquintinib·Sintilimab
Hutchmed
Phase 2/3
265
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2022-10-27
Recruiting
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
NCT05458219Locally Advanced Unresectable or Metastatic Solid Tumors
DrugsMFOLFOX·IBI343
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
470
Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha
2022-10-26
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou
2022-10-25
Active, closed
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
BeiGene
Phase 2
100
Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan
2022-10-25
Recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651Colorectal Neoplasms
DrugsLevoleucovorin·Tucatinib·Fluorouracil·Leucovorin
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Fuzhou, Lanzhou, Guangzhou, Meizhou, Haikou, Chengde, Tangshan, Harbin
2022-10-24
Active, closed
LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB
NCT05572957Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block
DrugGDMT
The First Affiliated Hospital with Nanjing Medical University
Not applicable
50
Beijing, Fuzhou, Nanjing, Dalian, Chengdu, Wenzhou
2022-10-14
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone
Janssen Research & Development, LLC
Phase 3
864
Beijing, Changchun, Changsha, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou
2022-10-13
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Hangzhou, Jiangxi, Jinan
2022-10-12
Active, closed
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
NCT06166836Solid Tumor
InxMed (Shanghai) Co., Ltd.
Phase 1/2
140
Hangzhou, Bengbu, Changsha, Fuzhou, Ganzhou, Nanjing, Wuhan, Xuzhou
2022-10-12
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
NCT06551220Metastatic Breast Cancer
DrugTrastuzumab deruxtecan
Sun Yat-sen University
Observational
800
Fuzhou, Dongguan, Foshan, Guangzhou, Shantou, Shaoguan, Shenzhen, Zhongshan
2022-10-10
Recruiting
Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks
NCT05230017Anti Phospholipid Syndrome
Peking Union Medical College Hospital
Observational
2,000
Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Hohhot, Nanjing, Nanchang
2022-10-01
Recruiting
Deeper Intubation Make Effects on Cervical Esophageal ESD
NCT06420258Carcinoma in Situ of Cervical Part of Esophagus
Fujian Provincial Hospital
Phase 4
40
Fuzhou
2022-10-01
Active, closed
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
NCT05535933Warm Antibody Autoimmune Hemolytic Anemia
Hutchmed
Phase 2/3
111
Fuyang, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Guilin, Haikou
2022-09-30
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05503264NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
DrugSatralizumab
Hoffmann-La Roche
Phase 3
122
Beijing, Chengdu, Fuzhou, Jining, Shanghai, Wenzhou
2022-09-27
Recruiting
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
DrugNipocalimab
Janssen Research & Development, LLC
Phase 2/3
201
Beijing, Changchun, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Jinan
2022-09-23
Active, closed
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066Follicular Lymphoma (FL)
DrugsEpcoritamab·Lenalidomide·Rituximab
Genmab
Phase 3
549
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2022-09-20
Active, closed
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugLitifilimab
Biogen
Phase 2/3
450
Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shenzhen, Zhongshan, Nanyang
2022-09-13
Recruiting
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505MRD
Guangdong Association of Clinical Trials
Phase 2
180
Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei
2022-09-13
Rows per page Showing 701–800 of 1018
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou?page=8

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,018 of those studies with a site in Fuzhou.

How many clinical trials are recruiting in Fuzhou?

594 of the 1,018 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 114 have not yet opened recruitment, 287 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.